НовостиBenzingaAgomab Therapeutics Doses First Patient In NOV-ERA, Global Phase 2b Study Evaluating Ontunisertib In Patients With Symptomatic FSCD Agomab Therapeutics Doses First Patient In NOV-ERA, Global Phase 2b Study Evaluating Ontunisertib In Patients With Symptomatic FSCD Benzinga 2026.10.13 20:06 (GMT+0) Открыть на Benzinga Другие новости